Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bad Blood: The Amgen/J&J Feud Takes a Perilous Turn

This article was originally published in RPM Report

Executive Summary

The longstanding feud between Amgen and Johnson & Johnson is bubbling over into a battle of bundled rebates. The fight carries broad repercussions for the pricing of biopharmaceuticals. The dispute threatens to compromise the new ASP payment system under Medicare Part B before it really gets going. Industry observers threat that the next step may be more direct price controls.

You may also be interested in...

The Slow Death of a Blockbuster

Bad news continues to mount for erythropoiesis-stimulating agents (ESAs), the flagship products of the biotechnology industry. Far from developing new markets, postmarket clinical trials by Amgen and J&J continue to point towards a much smaller appropriate patient population for Aranesp and Procrit.

Building the Right Foundation: An Interview with Mark McClellan

The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.

Relabeling EPO: Closing the Books on a Safety Issue, Opening a New Chapter at FDA

The relabeling of Aransep and Procrit to address safety issues is taking longer than expected. There's nothing new about that. What is new is how FDA weighed in on the Congressional debate over coverage for the anemia therapies-and how the last step of the regulatory process is likely to play out.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts